Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2996 Target Snapshot

Protein kinase C delta type · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,413Compounds
502Assays
8Approved Drugs
2,175.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein kinase C delta type shows clinical signal disease relevance led by myocardial infarction. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q05655. Start with myocardial infarction, then reuse UniProt Q05655 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with myocardial infarction, then reuse UniProt Q05655 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
myocardial infarction

Protein kinase C delta type shows clinical signal disease relevance led by myocardial infarction. 1 linked drug remains visible in the same block.

Start review with myocardial infarction because it currently carries clinical signal support. Linked drugs include DELCASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein kinase C delta type as ChEMBL target CHEMBL2996, mapped to UniProt Q05655. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein kinase C delta type
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2996
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q05655
Protein kinase C delta type
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Protein kinase C delta type is the right protein anchor across sources, using UniProt Q05655 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why myocardial infarction is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameProtein kinase C delta type
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ05655
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProtein kinase C delta type
UniProt AccessionQ05655
Component TypeProtein
Sequence Length676 aa

Protein kinase C delta type

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Protein kinase C delta type, mapped to UniProt Q05655. Sequence length is 676 aa.

Mapped IDQ05655
Review nameProtein kinase C delta type
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Protein kinase C delta type shows clinical signal disease relevance led by myocardial infarction.

Clinical signal Phase II
myocardial infarction
1 linked drug · 1 direct · 1 efficacy
Linked drugDELCASERTIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with myocardial infarction because it currently carries clinical signal support. Linked drugs include DELCASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemyocardial infarction
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

8
Approved
13
Phase III
20
Phase II
12
Phase I
Assay Mix

Activity Type Distribution

IC50713.0
KI1,005.0
EC5079.0
KD378.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2151411 10.0 IC50 0.1 Preclinical
CHEMBL5172923 9.96 Ki 0.11 Preclinical
CHEMBL5653589 9.89 Kd 0.129 Preclinical
CHEMBL388978 9.89 IC50 0.128 Preclinical
CHEMBL27768 9.71 Kd 0.193 Preclinical
CHEMBL2148106 9.7 Ki 0.2 Preclinical
CHEMBL417692 9.49 Ki 0.32 Preclinical
CHEMBL2418196 9.49 Ki 0.32 Preclinical
CHEMBL1996510 9.4 IC50 0.4 Preclinical
CHEMBL1256416 9.39 Ki 0.41 Preclinical
Distribution

pChEMBL Value Distribution

133
5.0
149
5.5
173
6.0
178
6.5
168
7.0
137
7.5
100
8.0
31
8.5
34
9.0
7
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
Properties Compare Identifier
ABEMACICLIB
CHEMBL3301610
Approved 2017
Properties Compare Identifier
INGENOL MEBUTATE
CHEMBL1863513
Approved 2010
Properties Compare Identifier
Assay Landscape

Assay Landscape

502
Total Assays
771
Tested Compounds
2
Assay Types
Binding — 498 assays, 771 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 378 673 6.9
cell-based format 58 24 6.7
assay format 51 42 7.2
subcellular format 10 28 6.2
cell membrane format 1 4 7.8
Functional — 4 assays, 233 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 4 233 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine